Oncolytics Biotech Files Routine 6-K Report
Ticker: ONCY · Form: 6-K · Filed: May 8, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, routine-report
TL;DR
Oncolytics Biotech filed a standard 6-K, no new news.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on May 8, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations sector. This filing does not appear to contain specific financial figures or material events beyond its routine reporting status.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is fulfilling its regular reporting obligations as a foreign private issuer with the SEC. It does not contain new material information for investors.
Risk Assessment
Risk Level: low — This is a routine SEC filing (Form 6-K) and does not contain new material information that would typically impact risk.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- 0001129928-24-000031 (filing_id) — Accession Number
- 20240508 (date) — Filing Date
- Calgary, Alberta, Canada (location) — Company Headquarters
FAQ
What type of SEC filing is this?
This is a Form 6-K, which is a Report of Foreign Private Issuer.
Who is the filer of this document?
The filer is Oncolytics Biotech Inc.
When was this filing submitted?
The filing was submitted on May 8, 2024.
Where is Oncolytics Biotech Inc. headquartered?
Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada.
Does this filing indicate a submission of an annual report?
The filing indicates that the registrant files annual reports under Form 20-F, not that this specific 6-K is an annual report.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-05-08 13:43:00
Filing Documents
- form6k2024rbcconf.htm (6-K) — 18KB
- oncy2024rbcconf.htm (EX-99.1) — 11KB
- 0001129928-24-000031.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date May 8, 2024 Kirk Look Chief Financial Officer